Selank: clinical evidence record
Also known as: TP-7, Threonine-Lysine-Proline-Arginine-Proline-Glycine-Proline
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Selank
Russian Federation registered medicine for generalised anxiety disorder. Russian clinical trial work reports anxiolytic effects without sedation or dependence profile. No published Western RCT data.
Mechanism of action
How Selank works
Synthetic heptapeptide derived from the immune-modulating tetrapeptide tuftsin. Proposed anxiolytic action via GABA-system modulation and enkephalin-degrading enzyme inhibition in preclinical Russian work. Administered as a nasal spray in the Russian clinical context.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on Selank. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
Selank in generalised anxiety disorder
Zozulia AA, Neznamov GG, Siuniakov TS, et al.. Zhurnal Nevrologii i Psikhiatrii im S S Korsakova, 2008.
-
Tuftsin analogues and their effects on the central nervous system
Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Neuroscience and Behavioral Physiology, 2003.
-
Selank effects on enkephalinase activity
Kost NV, Sokolov OY, Gabaeva MV, et al.. Bulletin of Experimental Biology and Medicine, 2001.
-
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.
Vyunova TV, Andreeva L, Shevchenko K, et al.. Protein and peptide letters, 2018.
-
Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.
Inozemtseva LS, Karpenko EA, Dolotov OV, et al.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2008.
-
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.
Kolik LG, Nadorova AV, Antipova TA, et al.. Bulletin of experimental biology and medicine, 2019.
-
Functional Connectomic Approach to Studying Selank and Semax Effects.
Panikratova YR, Lebedeva IS, Sokolov OY, et al.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020.
-
[Optimization of the treatment of anxiety disorders with selank].
Medvedev VE, Tereshchenko ON, Kost NV, et al.. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015.
-
[Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank].
Kolomin TA, Agapova TIu, Agniullin IaV, et al.. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2013.
-
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=Selank+tuftsin.
UK regulatory status
Plain-English summary of where Selank sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: Not currently listed on the WADA Prohibited List.
Risks and unknowns
What the literature does not yet show about Selank
Known concerns
- Most published efficacy claims for Selank require careful interpretation. Read the cited papers in full before drawing conclusions.
- Purity of UK research-peptide supply varies between retailers. Certificates of analysis and HPLC documentation differ.
- Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
- Independent replication of single-group findings is the key check on any preclinical claim.
Open questions in the literature
- Where human pharmacokinetics have not been formally characterised, dose translation from animal models is not reliable.
- Long-term safety profile beyond the duration of published studies remains an open question.
- Interactions with other prescribed or unlicensed substances are typically not studied.
Regulatory note
No UK marketing authorisation as a medicine. Not currently listed on the WADA Prohibited List. The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for Selank?
What is the UK regulatory status of Selank?
Has Selank been tested in human clinical trials?
Where can I read the source literature for Selank?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.